Krystal Biotech, Inc. Share Price
KRYSKrystal Biotech, Inc. Stock Performance
Open $260.72 | Prev. Close $260.40 | Circuit Range N/A |
Day Range $259.13 - $262.68 | Year Range $122.80 - $297.85 | Volume 6,521 |
Average Traded $261.12 |
Krystal Biotech, Inc. Share Price Chart
About Krystal Biotech, Inc.
Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). It also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1/2 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.
Krystal Biotech, Inc. Historical Data
| Day | Open | Close | Change % |
|---|---|---|---|
30-Apr-26 | $260.72 | $262.42 | +0.00% |
30-Apr-26 | $260.72 | $262.42 | -2.57% |
28-Apr-26 | $274.25 | $269.33 | -1.13% |
27-Apr-26 | $277.18 | $272.43 | -0.06% |
24-Apr-26 | $264.73 | $272.58 | +1.75% |
23-Apr-26 | $277.68 | $267.88 | -2.96% |
22-Apr-26 | $274.44 | $276.04 | +1.24% |